Literature DB >> 16547797

Assessment of basic indirect pharmacodynamic response models with physiological limits.

Zhenling Yao1, Wojciech Krzyzanski, William J Jusko.   

Abstract

Many physiological factors are regulated by homeostatic mechanisms to maintain normal body function. Empirical lower Rl (Model I and IV) or upper Rh limits (Model II and III) were included in current basic indirect response (IDR) models to account for the additional role of physiological limits (IDRPL). Various characteristics of these models were evaluated with simulations and explicit equations. The simulations reveal that the expanded models exhibit most properties of basic indirect response models, such as slow response initiation, lag time between the kinetic and dynamic peaks, a large dose plateau, and shift in Tmax with dose. The proposed models always produce lesser net responses than predicted by basic IDR models. Simulations demonstrate that addition of a parameter limit which is close to the baseline has a great influence on the overall and maximum responses and fitted model parameters. Only stimulatory IDRPL Models III and IV allow resolution of all model parameters in the absence of clear indications or predetermined values of the lower or upper limits. However, all four models are able to resolve model parameters when subgroups with different baselines are simultaneously fitted. These models create new interpretations of the determinants of baseline conditions which can be important in assessing inter-subject variability in responses. The applicability of IDRPL models is demonstrated using several examples from the published literature. Indirect response models with physiological limits will be useful in characterizing drug responses for turnover systems which are maintained within a certain range.

Mesh:

Substances:

Year:  2006        PMID: 16547797     DOI: 10.1007/s10928-006-9003-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  16 in total

1.  Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods.

Authors:  A Chakraborty; W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

2.  Asymptotics of the total net direct pharmacological effect for large drug doses.

Authors:  W Krzyzanski
Journal:  J Math Biol       Date:  2000-12       Impact factor: 2.259

3.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.

Authors:  A Sharma; W F Ebling; W J Jusko
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

4.  Integrated functions for four basic models of indirect pharmacodynamic response.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharm Sci       Date:  1998-01       Impact factor: 3.534

Review 5.  How is plasma calcium held constant? Milieu interieur of calcium.

Authors:  K Kurokawa
Journal:  Kidney Int       Date:  1996-06       Impact factor: 10.612

6.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

7.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

8.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

9.  Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.

Authors:  J M van Griensven; W J Jusko; H H Lemkes; R Kroon; C J Verhorst; S T Chiang; A F Cohen
Journal:  Clin Pharmacol Ther       Date:  1995-12       Impact factor: 6.875

10.  Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats.

Authors:  Rohini Ramakrishnan; Debra C DuBois; Richard R Almon; Nancy A Pyszczynski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

View more
  6 in total

Review 1.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

2.  Quantitative Systems Pharmacology: A Framework for Context.

Authors:  Ioannis P Androulakis
Journal:  Curr Pharmacol Rep       Date:  2016-04-08

3.  Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Authors:  Matthew M Riggs; Leo J Seman; Alexander Staab; Thomas R MacGregor; William Gillespie; Marc R Gastonguay; Hans J Woerle; Sreeraj Macha
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

4.  Methods of utilizing baseline values for indirect response models.

Authors:  Sukyung Woo; Dipti Pawaskar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-21       Impact factor: 2.745

5.  Turnover modeling of non-esterified fatty acids in rats after multiple intravenous infusions of nicotinic acid.

Authors:  Christine Isaksson; Johan Gabrielsson; Kristina Wallenius; Lambertus A Peletier; Helena Toreson
Journal:  Dose Response       Date:  2009-04-08       Impact factor: 2.658

6.  Quantitative Systems Pharmacology Model of NO Metabolome and Methemoglobin Following Long-Term Infusion of Sodium Nitrite in Humans.

Authors:  K Vega-Villa; R Pluta; R Lonser; S Woo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.